|
|
 | | | |
- close
- close
- close
- close
TRANSITION THERAPEUTICS (TTHI) |
StreetInsider.com
Apr 30
Comment
Delcath Systems (Nasdaq: DCTH) 41.7% LOWER; accelerated lower on Tuesday after the FDA said its Melblez Kit drug/device combo had a high treatment related death rate that would be replicated in a post-marketing setting even in a best case...
Benzinga
Apr 30
Comment
Transition Therapeutics Inc.
("Transition" or the "Company") (NASDAQ: TTHI) announced the results
of a five-week proof of concept clinical study of TT-401 in type 2 diabetic
and obese non-diabetic subjects. In the study, TT-401 a ...
StreetInsider.com
Aug 30
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Transition+Therapeutics+%28TTHI%29+Initiates+ELND005+Phase+2+with+First+Dosing/7694700.html for the full story.
Benzinga
Jun 18
Comment
Transition Therapeutics (Nasdaq: TTHI) announced the results of a single ascending dose escalation study of TT-401, a type 2 diabetes drug candidate. TT-401 is a once-weekly administered peptide being studied for its potential to lower blood...
Globe Newswire
May 14
Comment
TORONTO, May 14, 2012 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (TSX:TTH) (Nasdaq:TTHI) announced today that a mini-symposium entitled "The Emerging Clinical Profile of Oral Scyllo-inositol (ELND005) in
Globe Newswire
May 4
Comment
TORONTO, May 4, 2012 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (Nasdaq:TTHI) (TSX:TTH) will hold a conference call on Tuesday, May 8, 2012 at 4:30 P.M. EDT to discuss Third Quarter Fiscal 2012 financial results.
Globe Newswire
Apr 26
Comment
TORONTO, April 26, 2012 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (TSX:TTH) (Nasdaq:TTHI) announced that three ELND-005 poster presentations were presented yesterday at the American Academy of Neurology meeting
Globe Newswire
Mar 1
Comment
TORONTO, March 1, 2012 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (TSX:TTH), (Nasdaq:TTHI) announced today that Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition will be presenting at the Cowen &
Globe Newswire
Feb 7
Comment
TORONTO, Feb. 7, 2012 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (Nasdaq:TTHI) (TSX:TTH) will hold a conference call on Thursday, February 9, 2012 at 4:30 P.M. EST to discuss Second Quarter Fiscal 2012 financial
Benzinga
Dec 12
Comment
Transition Therapeutics Inc. (NASDAQ: TTHI) today announces the appointment of Ms. Nicole Rusaw-George, C.A., as Chief Financial Officer of Transition. Ms. George has been with the Company since 2005 and has served as Vice-President, Finance since...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS|
Error creating thumbnail: convert: unable to open image `/home/wikinvest/src_live_1/mediawiki/images/9/98/New_stock.png': No such file or directory @ blob.c/OpenBlob/2480. convert: unable to open file `/home/wikinvest/src_live_1/mediawiki/images/9/98/New_stock.png' @ png.c/ReadPNGImage/2889. convert: missing an image filename `/home/wikinvest/src_live_1/mediawiki/images/thumb/9/98/New_stock.png/35px-New_stock.png' @ convert.c/ConvertImageCommand/2800. |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
